191 related articles for article (PubMed ID: 38318268)
1. Maternal serum soluble fms-like tyrosine kinase-1-to-placental growth factor ratio distinguishes growth-restricted from non-growth-restricted small-for-gestational-age fetuses.
Rajiv P; Cade T; Dean J; Jones GD; Brennecke SP
AJOG Glob Rep; 2024 Feb; 4(1):100302. PubMed ID: 38318268
[TBL] [Abstract][Full Text] [Related]
2. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes.
Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
Am J Obstet Gynecol; 2021 May; 224(5):518.e1-518.e11. PubMed ID: 33166504
[TBL] [Abstract][Full Text] [Related]
3. Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia.
Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
Am J Obstet Gynecol; 2022 Aug; 227(2):294.e1-294.e11. PubMed ID: 35276067
[TBL] [Abstract][Full Text] [Related]
4. High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers.
Beck C; Allshouse A; Silver RM; Grobman WA; Simhan H; Haas D; Reddy UM; Blue NR
Am J Obstet Gynecol MFM; 2022 May; 4(3):100614. PubMed ID: 35283347
[TBL] [Abstract][Full Text] [Related]
5. Routine assessment of cerebroplacental ratio at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Akolekar R; Ciobanu A; Zingler E; Syngelaki A; Nicolaides KH
Am J Obstet Gynecol; 2019 Jul; 221(1):65.e1-65.e18. PubMed ID: 30878322
[TBL] [Abstract][Full Text] [Related]
6. Sequential plasma angiogenic factors levels in women with suspected preeclampsia.
Baltajian K; Bajracharya S; Salahuddin S; Berg AH; Geahchan C; Wenger JB; Thadhani R; Karumanchi SA; Rana S
Am J Obstet Gynecol; 2016 Jul; 215(1):89.e1-89.e10. PubMed ID: 26827880
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis.
Chaemsaithong P; Gil MM; Chaiyasit N; Cuenca-Gomez D; Plasencia W; Rolle V; Poon LC
Am J Obstet Gynecol; 2023 Sep; 229(3):222-247. PubMed ID: 36990308
[TBL] [Abstract][Full Text] [Related]
8. Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation.
Ciobanu A; Rouvali A; Syngelaki A; Akolekar R; Nicolaides KH
Am J Obstet Gynecol; 2019 May; 220(5):486.e1-486.e11. PubMed ID: 30707967
[TBL] [Abstract][Full Text] [Related]
9. Risk of adverse perinatal outcomes in pregnancies with "small" fetuses not meeting Delphi consensus criteria for fetal growth restriction.
Powel JE; Chavan NR; Zantow EW; Bialko MF; Farley LG; McCormick KM; Tomlinson TM
Am J Obstet Gynecol; 2023 Oct; 229(4):447.e1-447.e13. PubMed ID: 37767605
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
[TBL] [Abstract][Full Text] [Related]
11. Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction.
Dathan-Stumpf A; Czarnowsky V; Hein V; Andraczek T; Stepan H
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1037-S1047.e2. PubMed ID: 33892922
[TBL] [Abstract][Full Text] [Related]
12. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
[TBL] [Abstract][Full Text] [Related]
13. Maternal serum levels of soluble fms-like tyrosine kinase-1 and placental growth factor at 20 and 28 weeks of gestational age and the risk of spontaneous preterm birth.
Sovio U; Gaccioli F; Cook E; Charnock-Jones DS; Smith GCS
Am J Obstet Gynecol; 2023 Aug; 229(2):164.e1-164.e18. PubMed ID: 36758709
[TBL] [Abstract][Full Text] [Related]
14. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction.
Arenas GA; Tang NY; Mueller A; Lopes Perdigao J; Kaur H; Abramowicz JS; Mussatt K; Yeo KJ; Rana S
Am J Obstet Gynecol MFM; 2021 Jul; 3(4):100394. PubMed ID: 33991706
[TBL] [Abstract][Full Text] [Related]
15. An abnormal cerebroplacental ratio (CPR) is predictive of early childhood delayed neurodevelopment in the setting of fetal growth restriction.
Monteith C; Flood K; Pinnamaneni R; Levine TA; Alderdice FA; Unterscheider J; McAuliffe FM; Dicker P; Tully EC; Malone FD; Foran A
Am J Obstet Gynecol; 2019 Sep; 221(3):273.e1-273.e9. PubMed ID: 31226291
[TBL] [Abstract][Full Text] [Related]
16. Prenatal screening for preeclampsia: the roles of placental growth factor and pregnancy-associated plasma protein A in the first trimester and placental growth factor and soluble fms-like tyrosine kinase 1-placental growth factor ratio in the early second trimester.
Huang T; Rashid S; Priston M; Rasasakaram E; Mak-Tam E; Gibbons C; Mei-Dan E; Bedford HM
AJOG Glob Rep; 2023 May; 3(2):100193. PubMed ID: 37168546
[TBL] [Abstract][Full Text] [Related]
17. Fetal growth restriction and small for gestational age as predictors of neonatal morbidity: which growth nomogram to use?
Leon-Martinez D; Lundsberg LS; Culhane J; Zhang J; Son M; Reddy UM
Am J Obstet Gynecol; 2023 Dec; 229(6):678.e1-678.e16. PubMed ID: 37348779
[TBL] [Abstract][Full Text] [Related]
18. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of maternal serum insulin-like growth factor-I in pregnancies with appropriately grown or growth restricted fetuses.
Holmes RP; Holly JM; Soothill PW
Br J Obstet Gynaecol; 1998 Dec; 105(12):1273-8. PubMed ID: 9883918
[TBL] [Abstract][Full Text] [Related]
20. Prediction of imminent preeclampsia at 35-37 weeks gestation.
Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
